HealthTap has acquired Docphin, a medical research service that makes it easier for doctors to keep up to date with the latest medical news and research.
*Regarding LinkedIn* I generally don't connect with people on LinkedIn that don't comment on why they think we should connect. See: Use the “Favor Test” When You're Undecided About a LinkedIn Invitation [7/13/13] - @awsamuel @lifehacker http://ow.ly/AucoV ----------- I am a board certified hematologist / oncologist. I am passionate about clinical trials, basic science and translational research. It is a tragedy that only 2-7% of adults participate in cancer clinical trials (Zon R. et al. ASCO statement on minimum standards and exemplary attributes of clinical trial sites. J Clin Oncol. 2008) Improved clinical trial enrollment depends on well designed, interesting trials as well as informed patients that may even assist in clinical trial design. Institutional infrastructure support and local and national leadership with coordination are needed. The tumor treatment standards of care we have today in oncology are built upon the clinical trial leadership and patient participation of the past. Clinical trials benefit the individual and society and should be encouraged in the community setting. My goal is to offer patients the best therapy available for their individual situation. My PhD research was in pharmacogenetics. That is the study of how heredity changes one’s response to drugs (such as chemotherapy). I believe that this same personalized approach to drug research also applies to how I care for patients. Everyone is an individual. I am interested in cancer and hematologic or blood cancers -- eg lymphoma, myeloma, leukemia, and myelodysplastic syndrome (MDS). I am also interested in developing new treatments for all cancers, particularly early phase molecular biomarker driven studies. I believe that we live in an exciting era in which new drugs are providing options for improving quality of life and survival. Specialties: Hematology Oncology Clinical Research